AMAnita Medepalli

Anita Medepalli

*This is an algorithmically generated author record based on publicly available information.

Anita Medepalli has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Empowering Change Through Motivational Interviewing

    by Ebele M. Umeukeje, Anita Medepalli

    Was not provided for this article.

  • Rectal-cancer mimic of recurrent high-grade prostate adenocarcinoma

    by Anita Medepalli, Yoonhee Kim

    High-grade prostate cancer is usually monitored with prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography-CT (PET/CT). We describe an older man with a history of Gleason 9 prostate adenocarcinoma treated with androgen deprivation therapy, external beam radiotherapy and brachytherapy who later developed haematuria and functional decline. Despite a large invasive pelvic mass, his PSA remained undetectable, and PSMA PET/CT was negative, initially suggesting an alternative diagnosis such as rectal carcinoma. Colonoscopic biopsy was non-diagnostic, but prostate biopsy confirmed recurrent Gleason 9 adenocarcinoma. The patient deteriorated rapidly and died within 3 months. This case underscores the need for histological confirmation when PSA, PSMA PET/CT, and the clinical picture are discordant, even in previously well-controlled disease.

  • Open Access

    Diagnosis and management of a patient with 5 FU-induced ST elevation and nonsustained VT as a late presentation of cardiotoxicity and successful rechallenge of 5-FU

    by Lalitha C Medepalli, Tariq S.Mahmood, Henry Liberman, Anita M. Medepalli, Thomas W. Bagwell

    5-FU is an antimetabolite drug that is used to treat cancer. It is usually administered to decelerate and prohibit cancer cell proliferation. It acts by inhibiting the enzyme thymidylate synthase by blocking the thymidine formation required for DNA synthesis [1]. The most common clinical manifestation of 5-FU cardiotoxicity is chest pain related to coronary vasospasm [2]. An increase in endothelin-1, a vasoconstrictor, and a decrease in prostacyclin, a vasodilator, is thought to be the cause of endothelial dysfunction, which typically results in coronary vasospasm [3]. Cardiotoxicity induced by 5-FU carries a high risk of morbidity and mortality if it is left untreated [3]. Patients experiencing cardiotoxicity induced by 5-FU present with signs and symptoms of acute coronary syndromes with elevated cardiac biomarkers (troponin), and their ECGs often reveal ST segment differences. There can be two distinct clinical presentations, early or late presentation of cardiotoxicity. Usually, with early toxicity, troponin elevation may be evident. However, in late presentation of cardiotoxicity symptoms, troponin elevation and/or ECG changes may be undetectable. Our case has a unique presentation of 5-FU toxicity in a patient developing ST elevation and nonsustained ventricular tachycardia as a late presentation of cardiotoxicity. Despite the malignant presentation of this vasospasm with continuous infusion 5-FU administration (modified FOLFOX6), our patient was successfully treated and rechallenged with complete bolus 5-FU (FLOX) neoadjuvant chemotherapy. Chakrabarti, S. et al performed a retrospective review of approximately ten patients to explore the safety of substituting FLOX (bolus 5-FU, oxaliplatin, leucovorin) for FOLFOX (infusional 5-FU, oxaliplatin, leucovorin) and CAPOX (capecitabine, oxaliplatin) in patients who had 5-FU-induced coronary vasospasm. Out of the 10 patients, 8 patients had chest pain as the presenting complaint within 48 hours after beginning the 5-FU infusion. In 9 out of the 10 patients, coronary vasospasm occurred during the first cycle of therapy. All of the patients made a full recovery after the discontinuation of infusion of 5-FU or capecitabine. Subsequently, all patients received FLOX from 7 days to 18 months after the event, with 7 patients treated within 4 weeks of the event. FLOX did not cause any cardiovascular adverse events in any of the 10 patients [4]. Because our patient manifested malignant ST elevation and ventricular tachycardia during the late presentation coronary spasm with 5-FU, the cardio-oncology multidisciplinary team administered a vasodilator pre- and posttreatment regimen. This regimen was described previously in the literature for late presentation of 5-FU cardiotoxicity [5].